| Document Date: 2014-11-03 11:26:20
Open Document File Size: 16,99 KBShare Result on Facebook
City Osaka / / Company Shionogi & Co. Ltd. / BioCryst Pharmaceuticals Inc. / Corporate Communications Department Shionogi & Co. Ltd. / / Country Taiwan / Korea / Japan / United States / / Event FDA Phase / / / IndustryTerm treatment of infectious diseases / manufacturing approval / priority review product / foreign healthcare reforms / with respect to product / / MedicalCondition H1N1 influenza / adult uncomplicated seasonal influenza infection / infectious diseases / Infection / uncomplicated seasonal influenza / influenza A / Influenza / / Organization Ministry of Health / U.S. Food & Drug Administration / / Person Isao Teshirogi / / / Position President / / Product Shionogi Receives / RAPIACTA / /
SocialTag |
January 13, 2010 Shionogi & Co., Ltd. Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and